Tengrinews TV Радио Tengri FM Радио Жұлдыз FM Laws of Kazakhstan
KZ RU EN
Write us +7 (727) 388 8020 +7 (717) 254 2710
искать через Tengrinews.kz
искать через Google
искать через Yandex
USD / KZT - 335.71
EUR / KZT - 357.36
CNY / KZT - 48.76
RUB / KZT - 5.23

H7N9 vaccine may take months: US agency

12 april 2013, 16:30
0
©AFP
©AFP
Developing a vaccine for the H7N9 strain of bird flu that has killed 10 people in eastern China could take "many months", AFP reports citing US public health experts have.

Chinese authorities had confirmed 38 human cases of H7N9 avian influenza as of Thursday evening after announcing nearly two weeks ago that they had found the strain in humans for the first time.

Earlier vaccines targeting similar viruses had produced poor results, two members of the influenza division of the US Centers for Disease Control and Prevention (CDC) wrote in the New England Journal of Medicine.

"Even if new vaccine manufacturing technologies... are utilised, the process from vaccine development to availability will probably take many months," said Timothy Uyeki and Nancy Cox.

Although worldwide efforts to develop a vaccine had already started based on early cases, clinical trials would also be needed, said the article posted on the journal's website on Thursday.

The Chinese government said Wednesday that it expected to have a vaccine ready within seven months, state media reported.

China's Ministry of Science and Technology and the health ministry were jointly working on the vaccine, the Xinhua news agency said.

China has also developed a test for H7N9, distributing kits to hospitals and other monitoring sites, Xinhua said.

The journal article praised China's speed in identifying the virus, though it called for enhanced surveillance of people with respiratory illness and monitoring of the contacts of infected patients.

Chinese authorities say they do not know how the virus is spreading but they have so far ruled out human-to-human transmission, a conclusion echoed by the World Health Organization.

Нравится
Add comment
Most Read
Most Discussed